Drug Repurposing Revealed Abemaciclib and Palbociclib as Inhibitor of Phosphodiesterase-5 (PDE5) in Cancer-Associated Fibroblasts Paving the Way for the Treatment of Breast Cancer
Norah Saeed Al-Zahrani1, Ayyub Ali Patel1, Basiouny El-Gamal1,2★, Mohamed Abd Ellatif1,3, Khalid Ali Nasif1, Mohamed Babiker Abd Elrouf1, Heitham Mutwakil Mohammed4, Safaa Omer1, Marwa Saeed1, Muniera Mohieldeen1, Hagar Mohamed Mohamed5,6, Mohammad Rehan Ajmal7★ Corresponding author
- 1Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
- 2Healthcare and Pharma Department, Planaletix, Dubai, UNITED ARAB EMIRATES.
- 3Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, EGYPT.
- 4Department of Anatomy, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
- 5Department of Medical Laboratory Analysis, Faculty of Medical and Health Sciences, Liwa College, Abu Dhabi, UNITED ARAB EMIRATES.
- 6Department of Applied Medical Chemistry, Medical Research Institute, Alexandria University, Alexandria, EGYPT.
- 7Department of Biochemistry, Physical Biochemistry Research Laboratory, Faculty of Science, University of Tabuk, Tabuk, SAUDI ARABIA.
CORRESPONDENCE
Basiouny El-Gamal
Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, SAUDI ARABIA.
Received: 08-10-2024; Revised: 14-12-2024; Accepted: 22-03-2025.
Volume 59, Issue 3 · pp. 1221–1230 · PUBLISHED 2025 · DOI: 10.5530/ijper.20251022
ABSTRACT
Background: A common element of the tumor microenvironment, cancer-associated fibroblasts play a major role in the development of breast cancer via a variety of pathways. Studies show that cancer-associated fibroblasts over express phosphodiesterase-5 in comparison to normal fibroblasts and that this overexpression is linked to increased fibroblast activation and a more aggressive CAF phenotype. High PDE5 levels in CAFs contribute to the remodeling of the extracellular matrix, increased secretion of pro-tumorigenic factors and suppression of anti-tumor immune responses. Materials and Methods: Targeting PDE5 in CAFs thus offers a convincing method to interfere with these cells' pro-tumorigenic activities. The potential to inhibit PDE5 was examined for four FDA-approved CDK4/6 inhibitors: Abemaciclib, Palbociclib, Alvocidib and Ribociclib. Results: These drugs, with established safety profiles, were screened and docked against PDE5, showing binding affinities of -7.8, -7.8, -7.1 and -6.8 kcal/mol, respectively, compared to Sildenafil's -7.0 kcal/mol, a known inhibitor of PDE5. ADMET predictions, PASS analysis and Swiss Target Prediction affirmed their drug-like properties and potential for PDE5 inhibition. Conclusion: Based on these results, Abemaciclib and Palbociclib were chosen for in vitro experiments with cancer-associated fibroblasts. The 2 drugs significantly decreased the expression of PDE5 mRNA, indicating their potential as therapeutic agents for the treatment of breast cancer.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Al-Zahrani, N. S., Patel, A. A., El-Gamal, B., Ellatif, M. A., Nasif, K. A., Elrouf, M. B. A., Mohammed, H. M., Omer, S., Saeed, M., Mohieldeen, M., Mohamed, H. M., & Ajmal, M. R. (2025). Drug Repurposing Revealed Abemaciclib and Palbociclib as Inhibitor of Phosphodiesterase-5 (PDE5) in Cancer-Associated Fibroblasts Paving the Way for the Treatment of Breast Cancer. Indian Journal of Pharmaceutical Education and Research, 59(3), 1221–1230. https://doi.org/10.5530/ijper.20251022
